颅咽管瘤的靶向治疗
颅咽管瘤是鞍区罕见实性-囊性肿瘤,分为造釉细胞型和乳头型;乳头型多见BRAF-V600E突变,造釉细胞型多见CTNNB1/Wnt通路改变。本文综述靶向治疗现状:BRAF/MEK抑制在乳头型颅咽管瘤的辅助和新辅助治疗中显示持久肿瘤反应,CTNNB1/Wnt通路抑制剂在造釉细胞型临床前研究中显示希望并仍在研究中。
要点
- 乳头型颅咽管瘤多存在BRAF-V600E突变,造釉细胞型多存在CTNNB1/Wnt通路改变。
- BRAF/MEK抑制在乳头型颅咽管瘤辅助和新辅助治疗中显示持久肿瘤反应。
- CTNNB1/Wnt通路抑制剂在造釉细胞型临床前研究显示希望,仍在研究中。
核心结论
- BRAF/MEK抑制在乳头型颅咽管瘤中的疗效支持对新诊断乳头型颅咽管瘤患者使用靶向治疗。
- 最佳靶向治疗组合及其时机、持续时间、长期效应和与传统治疗模式的排序尚未确立,需进一步研究。
研究设计与样本
- 本文为综述,回顾乳头型和造釉细胞型颅咽管瘤靶向治疗的当前格局。
主要发现
- 多项病例研究和一项II期临床试验显示,BRAF/MEK抑制在辅助和新辅助治疗中使乳头型颅咽管瘤获得持久肿瘤反应。
- 造釉细胞型颅咽管瘤的治疗进展较有限,CTNNB1/Wnt通路抑制剂在临床前研究中显示希望并仍在研究中。
临床怎么用
- 作者认为,BRAF/MEK抑制在乳头型颅咽管瘤中的疗效支持对新诊断乳头型颅咽管瘤患者使用靶向治疗。
- 作者指出,最佳靶向治疗组合及其时机、持续时间、长期效应和与传统治疗模式的排序尚未确立,需进一步研究。
局限性
- 最佳靶向治疗组合及其时机、持续时间、长期效应和与传统治疗模式的排序尚未确立,需进一步研究。
- 造釉细胞型颅咽管瘤的靶向治疗进展较有限,CTNNB1/Wnt通路抑制剂仅见临床前研究结果并仍在研究中。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Craniopharyngioma is a rare solid-cystic tumor of the hypothalamopituitary region. Two distinct craniopharyngioma types (formerly subtypes), adamantinomatous and papillary, have been described. These tumors often manifest with neuroendocrine dysfunction, vision problems, hydrocephalus, and cognitive changes. Despite efforts to spare vital brain structures, conventional treatments such as surgery and radiation can exacerbate preceding deficits and contribute to permanent neurologic impairment. Recent studies have identified BRAF-V600E mutations in nearly all papillary craniopharyngiomas (PCP), and CTNNB1/Wnt pathway alterations in adamantinomatous craniopharyngiomas (ACP). These discoveries have advanced our understanding of craniopharyngioma pathogenesis and have opened opportunities for targeted biological treatments. PURPOSE: The primary objective of this article is to review the current landscape of targeted treatments in papillary and adamantinomatous craniopharyngioma. RESULTS: Treatment of PCP with BRAF/MEK inhibition has demonstrated durable tumor response in the adjuvant and neoadjuvant settings in multiple case studies and one phase II clinical trial. Although treatment advances are more limited for ACP, CTNNB1/Wnt pathway inhibitors showed promising results in pre-clinical studies and are under continued investigation. CONCLUSION: The efficacy of BRAF/MEK inhibition in PCP supports the use of targeted therapy in patients with newly diagnosed PCP. The optimal targeted treatment combinations and their timing, duration, long-term effects, and sequencing with traditional therapeutic modalities have not been established and warrant further study. Targeted therapies represent a significant advancement in the field of oncology, and craniopharyngiomas are viable candidates for these approaches pending further research.
引用
- Stec NE, Barker FG, Brastianos PK, et al. Targeted treatment for craniopharyngioma. J Neurooncol. 2025. PMID: 39951179. doi:10.1007/s11060-025-04942-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。